Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

11-06-2015 | Gastric cancer | Book chapter | Article

9. Endoscopy and Endoscopic Ultrasound Examination of the Stomach

Authors: Dr. Mark A. Schattner, MD, FACP, Dr. John Chi To Wong, MSc, MD

Publisher: Springer International Publishing

Login to get access

Abstract

As the fifth most frequently diagnosed cancer worldwide, and the third most common cause of cancer-related deaths, gastric cancer represents a significant cause of global morbidity and mortality. Gastrointestinal endoscopy plays an integral role in the screening, surveillance, diagnosis, and staging of gastric cancer. This chapter reviews the most recent evidence-based clinical and endoscopic practice for adenocarcinoma of the stomach.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013. http://​globocan.​iarc.​fr. Accessed 22 July 2014.
2.
Lin JT. Screening of gastric cancer: who, when, and how. Clin Gastroenterol Hepatol. 2014;12(1):135–8.PubMedCrossRef
3.
Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, Sobue T. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38(4):259–67.PubMedCrossRef
4.
Tsubono Y, Nishino Y, Tsuji I, Hisamichi S. Screening for gastric cancer in Miyagi, Japan: evaluation with a Population-Based Cancer Registry. Asian Pac J Cancer Prev. 2000;1(1):57–60.PubMed
5.
Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013;132(6):1272–6.PubMedCentralPubMedCrossRef
6.
Cho E, Kang MH, Choi KS, Suh M, Jun JK, Park EC. Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. Asian Pac J Cancer Prev. 2013;14(4):2533–40.PubMedCrossRef
7.
Choi KS, Jun JK, Park EC, Park S, Jung KW, Han MA, Choi IJ, Lee HY. Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One. 2012;7(11):e50041. doi:10.1371/journal.pone.0050041. (Epub 2012 Nov 29).PubMedCentralPubMedCrossRef
8.
Areia M, Carvalho R, Cadime AT, Rocha Gonçalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013;18(5):325–37.PubMedCrossRef
9.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRef
10.
Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211–7.PubMedCentralPubMedCrossRef
11.
Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, European Society of Gastrointestinal Endoscopy, European Helicobacter Study Group, European Society of Pathology, Sociedade Portuguesa de Endoscopia Digestiva, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44(1):74–94.PubMedCentralPubMedCrossRef
12.
Hirota WK, Zuckerman MJ, Adler DG, Davila RE, Standards of Practice Committee, American Society for Gastrointestinal Endoscopy, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63(4):570–80.PubMedCrossRef
13.
de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134(4):945–52.PubMedCrossRef
14.
Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2014;26(4):378–87.PubMedCrossRef
15.
Areia M, Amaro P, Dinis-Ribeiro M, Cipriano MA, et al. External validation of a classification for methylene blue magnification chromoendoscopy in premalignant gastric lesions. Gastrointest Endosc. 2008;67(7):1011–8.PubMedCrossRef
16.
Sipponen P, Price AB. The Sydney System for classification of gastritis 20 years ago. J Gastroenterol Hepatol. 2011;26(Suppl 1):31–4.PubMedCrossRef
17.
Eshmuratov A, Nah JC, Kim N, Lee HS, et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci. 2010;55(5):1364–75.PubMedCrossRef
18.
Lim JH, Kim N, Lee HS, Choe G, et al. Correlation between endoscopic and histological diagnoses of gastric intestinal metaplasia. Gut Liver. 2013;7(1):41–50.PubMedCentralPubMedCrossRef
19.
Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27(2):205–23.PubMedCrossRef
20.
Vannella L, Lahner E, Osborn J, Bordi C, Miglione M, Delle Fave G, Annibale B. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther. 2010;31(9):1042–50.PubMed
21.
O’Connor A, McNamara D, O'Moráin CA. Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer. Cochrane Database Syst Rev. 2013;9:CD009322. doi:10.1002/14651858.CD009322.pub2.
22.
You WC, Li JY, Blot WJ, Chang YS, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer. 1999;83(5):615–9.PubMedCrossRef
23.
Kim YJ, Park JC, Kim JH, Shin SK, Lee SK, Lee YC, Chung JB. Histologic diagnosis based on forceps biopsy is not adequate for determining endoscopic treatment of gastric adenomatous lesions. Endoscopy. 2010;42(8):620–6.PubMedCrossRef
24.
Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013;37(4):375–82.PubMedCrossRef
25.
Pharoah PD, Guilford P, Caldas C. International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.PubMedCrossRef
26.
Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54:3845–52.PubMed
27.
Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, International Gastric Cancer Linkage Consortium, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47(7):436.PubMedCentralPubMedCrossRef
28.
Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.PubMedCrossRef
29.
van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105:1258–64.PubMedCrossRef
30.
Beggs AD, Latchford AR, Vasen HF, Moslein G, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975–86.PubMedCrossRef
31.
Chun N, Ford JM. Genetic testing by cancer site: stomach. Cancer J. 2012;18(4):355–63.PubMedCrossRef
32.
Vasen HF, Möslein G, Alonso A, Aretz S, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57(5):704–13.PubMedCrossRef
33.
Bianchi LK, Burke CA, Bennett AE, Lopez R, Hasson H, Church JM. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6(2):180–5.PubMedCrossRef
34.
Ngamruengphong S, Boardman LA, Heigh RI, Krishna M, Roberts ME, Riegert-Johnson DL. Gastric adenomas in familial adenomatous polyposis are common, but subtle, and have a benign course. Hered Cancer Clin Pract. 2014;12(1):4.PubMedCentralPubMedCrossRef
35.
Renkonen-Sinisalo L, Sipponen P, Aarnio M. No support for endoscopic surveillance of gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol. 2002;37:574–7.PubMedCrossRef
36.
Park YJ, Shin K, Park J. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res. 2000;6:2994–8.PubMed
37.
Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, Vasen HF, Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010;138(2):487–92.PubMedCrossRef
38.
Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, et al. Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013; 62(6): 812–23.PubMedCentralPubMedCrossRef
39.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-society Task Force on colorectal cancer. Gastrointest Endosc. 2014;80(2):197–220.PubMedCrossRef
40.
Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.PubMedCentralPubMedCrossRef
41.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.CrossRef
42.
Yada T, Yokoi C, Uemura N. The current state of diagnosis and treatment for early gastric cancer. Diagn Ther Endosc. 2013;2013:241320. doi:10.1155/2013/241320. (Epub 2013 Feb 28).PubMedCentralPubMedCrossRef
43.
The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58(6 Suppl):S3–43.
44.
Choi J, Kim SG, Im JP, Kim JS, Jung HC, Song IS. Endoscopic prediction of tumor invasion depth in early gastric cancer. Gastrointest Endosc. 2011;73(5):917–27.PubMedCrossRef
45.
Kim JJ, Lee JH, Jung HY, Lee GH, et al. EMR for early gastric cancer in Korea: a multicenter retrospective study. Gastrointest Endosc. 2007;66(4):693–700.PubMedCrossRef
46.
Sakai Y, Eto R, Kasanuki J, Kondo F, et al. Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study. Gastrointest Endosc. 2008;68(4):635–41.PubMedCrossRef
47.
Lee BE, Kim GH, Park do Y, Kim DH, et al. Acetic acid-indigo carmine chromoendoscopy for delineating early gastric cancers: its usefulness according to histological type. BMC Gastroenterol. 2010;10:97.PubMedCentralPubMedCrossRef
48.
Uedo N, Fujishiro M, Goda K, Hirasawa D, et al. Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region. Dig Endosc. 2011;23(Suppl 1):58–71.PubMedCrossRef
49.
Hayee B, Inoue H, Sato H, Santi EG, Yoshida A, Onimaru M, Ikeda H, Kudo SE. Magnification narrow-band imaging for the diagnosis of early gastric cancer: a review of the Japanese literature for the Western endoscopist. Gastrointest Endosc. 2013;78(3):452–61.PubMedCrossRef
50.
Uedo N, Ishihara R, Iishi H, Yamamoto S, et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy. 2006;38(8):819–24.PubMedCrossRef
51.
Fujiwara S, Yao K, Nagahama T, Uchita K, et al. Can we accurately diagnose minute gastric cancers (≤ 5 mm)? Chromoendoscopy (CE) vs magnifying endoscopy with narrow band imaging (M-NBI). Gastric Cancer. 2014 (Jul 9. [Epub ahead of print]).
52.
Ajani JA, Bentrem DJ, Besh S, D’Amico TA, National Comprehensive Cancer Network, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11(5):531–46.PubMed
53.
Jeon HK, Ryu HY, Cho MY, Kim HS, et al. A randomized trial to determine the diagnostic accuracy of conventional vs. jumbo forceps biopsy of gastric epithelial neoplasias before endoscopic submucosal dissection; open-label study. Gastric Cancer. 2013 (Dec 13. [Epub ahead of print]).
54.
Fukase K, Kato M, Kikuchi S, Inoue K, Japan Gast Study Group, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392–7.PubMedCrossRef
55.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, ToGA Trial Investigators, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.PubMedCrossRef
56.
Lee HL, Eun CS, Lee OY, Han DS, Yoon BC, Choi HS, Hahm JS, Koh DH. When do we miss synchronous gastric neoplasms with endoscopy? Gastrointest Endosc. 2010;71(7):1159–65.PubMedCrossRef
57.
ASGE Standards of Practice Committee, Ben-Menachem T, Decker GA, Early DS, Evans J, Fanelli RD, Fisher DA, Fisher L, Fukami N, Hwang JH, Ikenberry SO, Jain R, Jue TL, Khan KM, Krinsky ML, Malpas PM, Maple JT, Sharaf RN, Dominitz JA, Cash BD. Adverse events of upper GI endoscopy. Gastrointest Endosc. 2012;76(4):707–18.PubMedCrossRef
58.
Parekh PJ. Merrell J1, Clary M1, Brush JE2, Johnson DA3. New anticoagulants and antiplatelet agents: a primer for the clinical gastroenterologist. Am J Gastroenterol. 2014;109(1):9–19.PubMedCrossRef
59.
Chen YI, Barkun AN, Soulellis C, Mayrand S, Ghali P. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: preliminary experience (with video). Gastrointest Endosc. 2012;75(6):1278–81.PubMedCrossRef
60.
ASGE Standards of Practice Committee, Banerjee S, Shen B, Baron TH, Nelson DB, Anderson MA, Cash BD, Dominitz JA, Gan SI, Harrison ME, Ikenberry SO, Jagannath SB, Lichtenstein D, Fanelli RD, Lee K, van Guilder T, Stewart LE. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67(6):791–8.PubMedCrossRef
61.
Shen L, Shan YS, Hu HM, Price TJ, et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535–47.PubMedCrossRef
62.
Cardoso R, Coburn N, Seevaratnam R, Sutradhar R, Lourenco LG, Mahar A, Law C, Yong E, Tinmouth J. A systematic review and meta-analysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S19–26.PubMedCrossRef
63.
Puli SR, Batapati Krishna Reddy J, Bechtold ML, Antillon MR, Ibdah JA. How good is endoscopic ultrasound for TNM staging of gastric cancers? A meta-analysis and systematic review. World J Gastroenterol. 2008;14(25):4011–9.PubMedCentralPubMedCrossRef
64.
Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. J Clin Oncol. 2007;25(15):2107–16.PubMedCrossRef
65.
Kim JH, Song KS, Youn YH, Lee YC, Cheon JH, Song SY, Chung JB. Clinicopathologic factors influence accurate endosonographic assessment for early gastric cancer. Gastrointest Endosc. 2007;66(5):901–8.PubMedCrossRef
66.
Bhutani MS, Hawes RH, Hoffman BJ. A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion. Gastrointest Endosc. 1997;45(6):474–9.PubMedCrossRef
67.
Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22.PubMedCrossRef
68.
Prasad P, Schmulewitz N, Patel A, Varadarajulu S, et al. Detection of occult liver metastases during EUS for staging of malignancies. Gastrointest Endosc. 2004;59(1):49–53.PubMedCrossRef
69.
Lee YT, Ng EK, Hung LC, Chung SC, Ching JY, Chan WY, Chu WC, Sung JJ. Accuracy of endoscopic ultrasonography in diagnosing ascites and predicting peritoneal metastases in gastric cancer patients. Gut. 2005;54(11):1541–5.PubMedCentralPubMedCrossRef
70.
DeWitt J, LeBlanc J, McHenry L, McGreevy K, Sherman S. Endoscopic ultrasound-guided fine-needle aspiration of ascites. Clin Gastroenterol Hepatol. 2007;5(5):609–15.PubMedCrossRef
71.
ASGE Standards of Practice Committee, Early DS, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Hwang JH, Jue TL, Khashab MA, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf RN, Shergill AK, Cash BD. Adverse events associated with EUS and EUS with FNA. Gastrointest Endosc. 2013;77(6):839–43.PubMedCrossRef
72.
Wang KX, Ben QW, Jin ZD, Du YQ, Zou DW, Liao Z, Li ZS. Assessment of morbidity and mortality associated with EUS-guided FNA: a systematic review. Gastrointest Endosc. 2011;73(2):283–90.PubMedCrossRef